Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29563535 | 0.84 | TP53 (0.51) | CYP3A4SMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL559935 | 0.84 | TP53 (0.51) | CYP3A4SMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL3087777 | 0.83 | CYP3A4 (0.91) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| Nitromide SCHEMBL193674 | 0.83 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL14586132 | 0.83 | ALDH1A1 (0.53) | CYP3A4SMN1; SMN2TSHRALDH1A1CES2 | |
| SCHEMBL14282753 | 0.83 | ALDH1A1 (0.53) | CYP3A4SMN1; SMN2TSHRLMNAALDH1A1 | |
| Nitromide SCHEMBL17803670 | 0.81 | CYP3A4 (0.96) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL6330190 | 0.81 | CYP19A1 (0.54) | CYP3A4SMN1; SMN2TSHRLMNAALDH1A1 | |
| SCHEMBL3789244 | 0.79 | PARP1 (0.40) | CYP3A4SMN1; SMN2TSHRALDH1A1PARP1 | |
| SCHEMBL23641285 | 0.79 | CYP3A4 (0.42) | CYP3A4SMN1; SMN2TSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-101679408-B | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2016-04-27 | — | — | CN | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| WO-2014133549-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014133547-A1 | TARGETED NANOPARTICLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | CYP3A4 1359/4885SMN1; SMN2 3919/4885TSHR 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.